40m And Bigger

Rgenix generates $40m series C
The Rockefeller spinout will use the series C proceeds to advance two cancer drug candidates through early-stage clinical trials.
PGDx intersects with Innovatus in $42m deal
Johns Hopkins oncology diagnostics spinout PGDx had previously raised approximately $99m.
Morphic shapes $80m series B
Novo has co-led a series B round together with Omega Funds for Morphic Therapeutic, based on research by Harvard professor Timothy Springer.
Investors go with gut in $83m UBiome round
Stanford-StartX Fund-backed microbial diagnostics and wellness product developer UBiome has raised $83m in series C funding.
Atreca carries on funding streak
OncoResponse answers questions with $40m series B
Helsinn Investment Fund and Alexandria Venture Investments both invested as MD Anderson-backed OncoResponse looks to advance five immuno-oncology drug candidates.
Twentyeight-Seven counts down to $65m series A
Twentyeight-Seven Therapeutics has officially launched with $65m in series A funding to commercialise oncology treatments based on research at Harvard Medical School.
Allogene tallies up $120m
The cancer therapy developer has secured $120m in a convertible note offering featuring the University of California office of the chief investment officer.

Other News

4D Molecular forces its way to $90m
Berkeley Catalyst Fund has helped close a $90m series B round for 4D Molecular Therapeutics, which emerged out of UC Berkeley.
Evox voices $45.4m series B
Oxford Sciences Innovation has contributed to a series B round for Evox Therapeutics, a spinout of University of Oxford that has also added GV as a shareholder.
Principia Biopharma primes $86m IPO
Principia Biopharma, whose drug discovery platform is based on research at UCSF, has filed for an $86.3m initial public offering having raised $50m earlier this month.
Pfizer coughs up funding for Biontech
Biontech, an immunotherapy spinout of Johannes Gutenberg University Mainz, has received an undisclosed amount of equity funding as part of a collaboration deal that could reach $425m.
Corporates help plant $150m in Orchard
Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.

Editor's Picks

Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Big deal: QuantumScape fuels up on VW cash
VW will invest $100m in QuantumScape and form a joint venture with the Stanford spinout to develop batteries for long-range electric vehicles.
Big deal: NMD flexes series A muscles
Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.
Big deal: Touchstone helps inject $73m into Cell Medica
Touchstone Innovations, which co-founded the cellular immunotherapy developer in 2007, has contributed to another funding round.
test reg

Login

Not yet subscribed?

See your subscription offers here